期刊
DIGESTIVE DISEASES AND SCIENCES
卷 67, 期 2, 页码 408-422出版社
SPRINGER
DOI: 10.1007/s10620-021-07317-3
关键词
Improvement of NAFLD; Mechanisms; Risks of surgery; Cirrhosis; Liver transplant; Cost analysis
Currently, there are no approved medications for patients with NASH-related liver disease. Lifestyle modifications are often ineffective in achieving weight reduction in these patients. Bariatric surgery may be considered as an option for those who fail to lose weight through lifestyle changes. It has shown to improve liver histology and other comorbidities, as well as reduce cardiovascular morbidity and mortality.
Currently, there are no approved medications to treat patients with nonalcoholic steatohepatitis (NASH) with fibrosis or cirrhosis. Although the management goal in these patients is weight reduction by 7-10% with lifestyle modifications, only less than 10% of patients achieve this target at 1-year, and fewer maintain the weight loss at 5 years. Bariatric surgery is an option that may be considered in those who fail to lose weight by lifestyle changes. Bariatric surgery has been shown to improve liver histology including fibrosis secondary to NASH, in addition to other benefits including an improvement or resolution of type 2 diabetes mellitus, dyslipidemia, and hypertension, and a reduction of cardiovascular morbidity or mortality. There are no guidelines of bariatric surgery indications for the management of NASH. The purpose of this review is to critically appraise the current knowledge of the role of bariatric surgery and the potential mechanisms for its perceived benefits in the management of patients with NASH-related liver disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据